Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation.

PubWeight™: 1.20‹?› | Rank: Top 10%

🔗 View Article (PMID 9531270)

Published in J Immunol on April 01, 1998

Authors

V Haridas1, B G Darnay, K Natarajan, R Heller, B B Aggarwal

Author Affiliations

1: Department of Molecular Oncology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Articles citing this

Type V protein secretion pathway: the autotransporter story. Microbiol Mol Biol Rev (2004) 5.80

TNF-induced signaling in apoptosis. J Clin Immunol (1999) 1.71

Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J (1999) 1.59

TNF ligands and receptors--a matter of life and death. Br J Pharmacol (2002) 1.57

Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. Ann Rheum Dis (2000) 1.48

In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-α-induced apoptosis and proliferation by MAPKs. Sci Signal (2011) 1.37

Receptor-mediated choreography of life and death. J Clin Immunol (2003) 1.33

Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-kappaB by inhibiting both its nuclear localization and ability to bind DNA. Proc Natl Acad Sci U S A (2001) 1.30

Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine (2007) 1.28

A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol (2002) 1.26

Proinflammatory and proapoptotic activities associated with Bordetella pertussis filamentous hemagglutinin. Infect Immun (2001) 1.25

TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm (2010) 1.20

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R. J Exp Med (1998) 1.06

Infection of human fallopian tube epithelial cells with Neisseria gonorrhoeae protects cells from tumor necrosis factor alpha-induced apoptosis. Infect Immun (2006) 1.03

Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochem J (2001) 1.00

Akt-dependent NF-kappaB activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res (2008) 1.00

Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc Natl Acad Sci U S A (2007) 0.97

TNF-alpha is involved in activating DNA fragmentation in skeletal muscle. Br J Cancer (2002) 0.97

Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating EGFR-dependent PI3K/Akt signaling. J Cell Physiol (2008) 0.93

The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis (2000) 0.91

Life and death of lymphocytes: a role in immunesenescence. Immun Ageing (2005) 0.88

Levels of salivary IFN-gamma, TNF-alfa, and TNF receptor-2 as prognostic markers in (erosive) oral lichen planus. Mediators Inflamm (2011) 0.83

The expression of tumor necrosis factor-alpha, its receptors and steroidogenic acute regulatory protein during corpus luteum regression. Reprod Biol Endocrinol (2008) 0.82

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol (2016) 0.81

Tumour necrosis factor-induced activation of c-Jun N-terminal kinase is sensitive to caspase-dependent modulation while activation of mitogen-activated protein kinase (MAPK) or p38 MAPK is not. Biochem J (2002) 0.79

Differential sensitivity of naïve and memory subsets of human CD8+ T cells to TNF-alpha-induced apoptosis. J Clin Immunol (2006) 0.79

Gene therapy that inhibits NF-kappaB results in apoptosis of human hepatocarcinoma by recombinant adenovirus. World J Gastroenterol (2006) 0.77

Colocalization of endogenous TNF with a functional intracellular splice form of human TNF receptor type 2. J Inflamm (Lond) (2005) 0.77

Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinoma. Biomed Res Int (2013) 0.77

FOXO3a regulates oxygen-responsive expression of tumor necrosis factor receptor 2 in human dermal microvascular endothelial cells. J Biol Chem (2009) 0.77

Tumor necrosis factor receptor 2 (TNFR2)·interleukin-17 receptor D (IL-17RD) heteromerization reveals a novel mechanism for NF-κB activation. J Biol Chem (2014) 0.75

Synthesis, characterization and in vitro anticancer activity of C-5 curcumin analogues with potential to inhibit TNF-α-induced NF-κB activation. Biomed Res Int (2014) 0.75

Id2 regulates the proliferation of squamous cell carcinoma in vitro via the NF-κB/Cyclin D1 pathway. Chin J Cancer (2012) 0.75

Down-regulation of microRNA-155 promotes selenium deficiency-induced apoptosis by tumor necrosis factor receptor superfamily member 1B in the broiler spleen. Oncotarget (2017) 0.75

Articles by these authors

Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A (1996) 24.18

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science (1985) 7.99

Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. J Immunol (1985) 7.20

Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem (1985) 6.28

Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature (1985) 5.41

Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature (1986) 4.98

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science (2001) 4.89

Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A (1996) 4.11

Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem (1995) 4.05

Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol (2000) 2.86

Johann Christian Reil's training scheme for medical auxiliaries. Med Hist (1975) 2.77

NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56

Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem (1984) 2.55

Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48

Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem (1999) 2.44

Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem (1999) 2.41

Tumor necrosis factors: gene structure and biological activities. Cold Spring Harb Symp Quant Biol (1986) 2.38

Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33

Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol (1985) 2.31

Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem (1998) 2.26

Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia (2002) 2.26

Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw (1996) 2.18

The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer (1998) 2.11

Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09

Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05

Officiers de santé: the second-class doctors of nineteenth-century France. Med Hist (1978) 1.96

Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science (1987) 1.92

Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci U S A (1986) 1.91

Structure and organization of the highly repeated and interspersed 1.3 kb EcoRI-Bg1II sequence family in mice. Nucleic Acids Res (1980) 1.89

The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin. J Immunol (1984) 1.81

Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha. J Leukoc Biol (1987) 1.81

Randomized 4-week exercise program in patients with impaired left ventricular function. Circulation (1991) 1.77

Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett (1998) 1.75

TNF-induced signaling in apoptosis. J Clin Immunol (1999) 1.71

Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature (1999) 1.69

Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene (2006) 1.68

Antitumor activity of the novel human breast cancer growth inhibitor, mammary-derived growth inhibitor-related gene, MRG. Cancer Res (1997) 1.66

Assay for redox-sensitive transcription factor. Methods Enzymol (2000) 1.65

The role of polymeric surface smoothness of biliary stents in bacterial adherence, biofilm deposition, and stent occlusion. Gastrointest Endosc (1993) 1.64

Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood (2001) 1.64

Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem (1985) 1.64

Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet (2006) 1.62

Bacteremia and endocarditis caused by a Gordonia species in a patient with a central venous catheter. Emerg Infect Dis (2000) 1.61

Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 1.58

Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet (2008) 1.57

Coyotes (Canis latrans) as the reservoir for a human pathogenic Bartonella sp.: molecular epidemiology of Bartonella vinsonii subsp. berkhoffii infection in coyotes from central coastal California. J Clin Microbiol (2000) 1.56

Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Ther (2010) 1.56

Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia (2001) 1.56

Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. BJOG (2012) 1.53

Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol (1998) 1.51

Epidemiology of Bartonella infection in domestic cats in France. Vet Microbiol (2001) 1.49

Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol (1987) 1.49

Identification of seven hydrophobic clusters in GCN4 making redundant contributions to transcriptional activation. Mol Cell Biol (1996) 1.47

Coinfection with Bartonella clarridgeiae and Bartonella henselae and with different Bartonella henselae strains in domestic cats. J Clin Microbiol (1997) 1.46

The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet (1980) 1.45

Magnetic resonance imaging, Down's syndrome and Alzheimer's disease: research and clinical implications. J Intellect Disabil Res (2003) 1.42

A T cell receptor transgenic model of severe, spontaneous organ-specific autoimmunity. Eur J Immunol (2001) 1.41

Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet (2007) 1.41

TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol (1994) 1.41

Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem (1998) 1.40

Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res (1988) 1.39

Outcome with calcium channel antagonists after myocardial infarction: a community-based study. J Am Coll Cardiol (1998) 1.39

Human tumor necrosis factor-alpha receptor. Purification by immunoaffinity chromatography and initial characterization. J Biol Chem (1988) 1.38

Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol (2000) 1.37

Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene (2007) 1.36

Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem (1998) 1.36

Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol (1999) 1.33

Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. Cancer Res (2000) 1.33

Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene (2006) 1.33

Tumor necrosis factors alpha and beta differ in their capacities to generate interleukin 1 release from human endothelial cells. J Immunol (1987) 1.32

Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes. Hybridoma (1987) 1.31

Theory and in vivo application of electroporative gene delivery. Mol Ther (2000) 1.30

Ectopic expression of hepatitis C virus core protein differentially regulates nuclear transcription factors. J Virol (1998) 1.29

VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J (1999) 1.29

Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs (1997) 1.27

Bartonella birtlesii sp. nov., isolated from small mammals (Apodemus spp.). Int J Syst Evol Microbiol (2000) 1.27

TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J (1998) 1.25

Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol (2001) 1.24

Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cells. Proc Natl Acad Sci U S A (1988) 1.23

Early events in TNF signaling: a story of associations and dissociations. J Leukoc Biol (1997) 1.23

Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol (1999) 1.23

Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes. J Clin Invest (1989) 1.22

Comparison of processes and intermediate outcomes between South Asian and European patients with diabetes in Blackburn, north-west England. Diabet Med (2005) 1.22

In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: possible roles in malaria. Infect Immun (1992) 1.21

Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation. J Biol Chem (1997) 1.21

Identification of the principal catalytically important acidic residue of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Biol Chem (1990) 1.20

Post-thymectomy autoimmune gastritis: fine specificity and pathogenicity of anti-H/K ATPase-reactive T cells. Eur J Immunol (1999) 1.20

Activation of CPP32-like protease in tumor necrosis factor-induced apoptosis is dependent on mitochondrial function. J Clin Invest (1997) 1.20

Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett (1994) 1.20

Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A (1995) 1.20

Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, IkappaB degradation, and expression of cell surface adhesion proteins in human vascular endothelial cells. Oncogene (1998) 1.19

Identification and characterisation of childhood cerebellar tumours by in vivo proton MRS. NMR Biomed (2008) 1.19

Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs (2000) 1.19

Comparative phylogeography of African savannah ungulates. Mol Ecol (2012) 1.18

Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response. J Biol Chem (1994) 1.18

Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol (1998) 1.17